8:45am ET
Investing
The Biggest IPO of the Year Prompts Huge Insider Buy
Kodiak Sciences, Medline, and W.R. Berkley have seen some huge insider purchases, and there were some other notable insider purchases as well..
Companies
/Healthcare
Entrada Therapeutics Inc
Today · % change
Fundamentals
Market Cap
$283.1M
Revenue (TTM)
$4.7M
EPS (TTM)
$-3.96
52-Week Range
$5 – $16
Street Target
$19.00
About Entrada Therapeutics
Entrada Therapeutics, based in Boston, Massachusetts, is a pioneering biotechnology firm focused on creating treatments for neuromuscular diseases. Using its innovative endosomal escape vehicle (EEV) platform, the company is developing a diverse portfolio that includes oligonucleotide, antibody, and enzyme-based therapies. Its leading candidates are aimed at tackling Duchenne muscular dystrophy and myotonic dystrophy type 1, with key projects like ENTR-601-44 and ENTR-601-45 in preclinical trials. Entrada also collaborates with Vertex Pharmaceuticals to advance its mission of bringing novel therapies to patients in need.
